170 related articles for article (PubMed ID: 19737948)
1. Inhibition of ALK signaling for cancer therapy.
Mossé YP; Wood A; Maris JM
Clin Cancer Res; 2009 Sep; 15(18):5609-14. PubMed ID: 19737948
[TBL] [Abstract][Full Text] [Related]
2. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
3. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
6. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
9. Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells.
Gouzi JY; Moog-Lutz C; Vigny M; Brunet-de Carvalho N
J Cell Sci; 2005 Dec; 118(Pt 24):5811-23. PubMed ID: 16317043
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
11. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
12. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
Tothova Z; Wagner AJ
Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
[TBL] [Abstract][Full Text] [Related]
14. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
15. The emerging normal and disease-related roles of anaplastic lymphoma kinase.
Pulford K; Lamant L; Espinos E; Jiang Q; Xue L; Turturro F; Delsol G; Morris SW
Cell Mol Life Sci; 2004 Dec; 61(23):2939-53. PubMed ID: 15583856
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
17. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M
Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of anaplastic lymphoma kinase: a patent review.
Milkiewicz KL; Ott GR
Expert Opin Ther Pat; 2010 Dec; 20(12):1653-81. PubMed ID: 20961208
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
20. The anaplastic lymphoma kinase in the pathogenesis of cancer.
Chiarle R; Voena C; Ambrogio C; Piva R; Inghirami G
Nat Rev Cancer; 2008 Jan; 8(1):11-23. PubMed ID: 18097461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]